These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 29423950)

  • 1. Guideline-Directed Medical Therapy and Survival Following Hospitalization in Patients with Heart Failure.
    Tran RH; Aldemerdash A; Chang P; Sueta CA; Kaufman B; Asafu-Adjei J; Vardeny O; Daubert E; Alburikan KA; Kucharska-Newton AM; Stearns SC; Rodgers JE
    Pharmacotherapy; 2018 Apr; 38(4):406-416. PubMed ID: 29423950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community.
    Dunlay SM; Killian JM; Roger VL; Schulte PJ; Blecker SB; Savitz ST; Redfield MM
    J Card Fail; 2022 Oct; 28(10):1500-1508. PubMed ID: 35902033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction.
    Givertz MM; Stevenson LW; Costanzo MR; Bourge RC; Bauman JG; Ginn G; Abraham WT;
    J Am Coll Cardiol; 2017 Oct; 70(15):1875-1886. PubMed ID: 28982501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the prescribing practice of guideline-directed medical therapy among ambulatory chronic heart failure patients.
    Parajuli DR; Shakib S; Eng-Frost J; McKinnon RA; Caughey GE; Whitehead D
    BMC Cardiovasc Disord; 2021 Feb; 21(1):104. PubMed ID: 33602125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between a hospitalization for heart failure and the initiation/discontinuation of guideline-recommended treatments: An analysis from the Swedish Heart Failure Registry.
    Schrage B; Lund LH; Benson L; Braunschweig F; Ferreira JP; Dahlström U; Metra M; Rosano GMC; Savarese G
    Eur J Heart Fail; 2023 Jul; 25(7):1132-1144. PubMed ID: 37317585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing Guideline-Directed Medication Therapy for Heart Failure in End-Stage Renal Disease.
    Cutshall BT; Duhart BT; Saikumar J; Samarin M; Hutchison L; Hudson JQ
    Am J Med Sci; 2018 Mar; 355(3):247-251. PubMed ID: 29549927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry.
    Greene SJ; Butler J; Hellkamp AS; Spertus JA; Vaduganathan M; Devore AD; Albert NM; Patterson JH; Thomas L; Williams FB; Hernandez AF; Fonarow GC
    J Card Fail; 2022 Mar; 28(3):370-384. PubMed ID: 34793971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guideline-Directed Medication Use in Patients With Heart Failure With Reduced Ejection Fraction in India: American College of Cardiology's PINNACLE India Quality Improvement Program.
    Pokharel Y; Wei J; Hira RS; Kalra A; Shore S; Kerkar PG; Kumar G; Risch S; Vicera V; Oetgen WJ; Deswal A; Turakhia MP; Glusenkamp N; Virani SS
    Clin Cardiol; 2016 Mar; 39(3):145-9. PubMed ID: 26880649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns, Prognostic Implications, and Rural-Urban Disparities in Optimal GDMT Following HFrEF Diagnosis Among Medicare Beneficiaries.
    Mentias A; Keshvani N; Sumarsono A; Desai R; Khan MS; Menon V; Hsich E; Bress AP; Jacobs J; Vasan RS; Fonarow GC; Pandey A
    JACC Heart Fail; 2024 Jun; 12(6):1044-1055. PubMed ID: 37943222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction.
    Kocabaş U; Ergin I; Kıvrak T; Yılmaz Öztekin GM; Tanık VO; Özdemir İ; Avcı Demir F; Doğduş M; Şen T; Altınsoy M; Üstündağ S; Urgun ÖD; Sinan ÜY; Uygur B; Yeni M; Özçalık E
    ESC Heart Fail; 2023 Dec; 10(6):3677-3689. PubMed ID: 37804042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Digoxin Discontinuation and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction.
    Malik A; Masson R; Singh S; Wu WC; Packer M; Pitt B; Waagstein F; Morgan CJ; Allman RM; Fonarow GC; Ahmed A
    J Am Coll Cardiol; 2019 Aug; 74(5):617-627. PubMed ID: 31370952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients.
    Srivastava PK; DeVore AD; Hellkamp AS; Thomas L; Albert NM; Butler J; Patterson JH; Spertus JA; Williams FB; Duffy CI; Hernandez AF; Fonarow GC
    JACC Heart Fail; 2021 Jan; 9(1):28-38. PubMed ID: 33309579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Optimizing Guideline-Directed Medical Therapy Before Discharge on Mortality and Heart Failure Readmission in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.
    Yamaguchi T; Kitai T; Miyamoto T; Kagiyama N; Okumura T; Kida K; Oishi S; Akiyama E; Suzuki S; Yamamoto M; Yamaguchi J; Iwai T; Hijikata S; Masuda R; Miyazaki R; Hara N; Nagata Y; Nozato T; Matsue Y
    Am J Cardiol; 2018 Apr; 121(8):969-974. PubMed ID: 29477488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frailty interferes with the guideline-directed medical therapy in heart failure patients with reduced ejection fraction.
    Hamada T; Kubo T; Kawai K; Nakaoka Y; Yabe T; Furuno T; Yamada E; Kitaoka H;
    ESC Heart Fail; 2023 Feb; 10(1):223-233. PubMed ID: 36193578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing Guideline-Directed Medical Therapy During Hospitalization Improves Prognosis in Patients With Worsening Heart Failure Requiring Readmissions.
    Matsukawa R; Kabu K; Koga E; Hara A; Kisanuki H; Sada M; Okabe K; Okahara A; Tokutome M; Kawai S; Ogawa K; Matsuura H; Mukai Y
    Circ J; 2024 Aug; 88(9):1416-1424. PubMed ID: 39034132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription Rates and Prognostic Implications of Optimally Targeted Guideline-Directed Medical Treatment in Heart Failure and Atrial Fibrillation: Insights From The MISOAC-AF Trial.
    Moysidis DV; Kartas A; Samaras A; Papazoglou AS; Patsiou V; Bekiaridou A; Baroutidou A; Tsagkaris C; Karagiannidis E; Daios S; Anastasiou V; Tsalikakis D; Efthimiadis G; Ziakas A; Tzikas A; Giannakoulas G
    J Cardiovasc Pharmacol; 2023 Mar; 81(3):203-211. PubMed ID: 36626410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies.
    Premchand RK; Sharma K; Mittal S; Monteiro R; Libbus I; Ardell JL; Gregory DD; KenKnight BH; Amurthur B; DiCarlo LA; Anand IS
    ESC Heart Fail; 2019 Oct; 6(5):1052-1056. PubMed ID: 31339232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Pharmacist-Led Heart Failure Clinic on Optimization of Guideline-Directed Medical Therapy (PHARM-HF).
    Patil T; Ali S; Kaur A; Akridge M; Eppes D; Paarlberg J; Parashar A; Jarmukli N
    J Cardiovasc Transl Res; 2022 Dec; 15(6):1424-1435. PubMed ID: 35501544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in provider approach to initiating and titrating guideline directed medical therapy in heart failure with reduced ejection fraction.
    Cordwin DJ; Guidi J; Alhashimi L; Hummel SL; Koelling TM; Dorsch MP
    BMC Cardiovasc Disord; 2024 May; 24(1):247. PubMed ID: 38730379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial.
    Fiuzat M; Ezekowitz J; Alemayehu W; Westerhout CM; Sbolli M; Cani D; Whellan DJ; Ahmad T; Adams K; Piña IL; Patel CB; Anstrom KJ; Cooper LS; Mark D; Leifer ES; Felker GM; Januzzi JL; O'Connor CM
    JAMA Cardiol; 2020 Jul; 5(7):757-764. PubMed ID: 32319999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.